Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04137900
Recruitment Status : Recruiting
First Posted : October 24, 2019
Last Update Posted : November 1, 2019
Sponsor:
Collaborators:
CTI Clinical Trial and Consulting Services
TopAlliance Biosciences, Inc.
Information provided by (Responsible Party):
Shanghai Junshi Bioscience Co., Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : January 2023